

OXiGENE, Inc. VTA Bi-Weekly Teleconference

Meeting Minutes for September 17, 2002

Participants:

Oxigene:

Fred Driscoll
Joe Prezioso
Scott Young
Dai Chaplin
James Velema

Baylor Univ.:

Kevin Pinney
Bob Kane
Charles Garner

Lund University:

Klaus Edvardsen

1.0 Preclinical Update

The next VTA conference call is scheduled for October 1, 2002. Conference calls will be scheduled every other Tuesday at 10:00 a.m. Kevin Pinney prior to the conference call will provide a chemistry summary sheet of compounds worked on at Baylor in the prior two weeks.

Biological Studies

- Klaus will compile all the rat propranolol data with CA4P into a report and send it to Dai and myself.
- Klaus performed a single dose MTD study with the indole monophosphate (Oxi3189). The dose levels tested were 400, 800 and 1200 mg/kg. Klaus stated that the MTD for the indole monophosphate at a single dose was 800 mg/kg.

CA1

- Kevin and Bob's groups are synthesizing two novel CA1P analogs (2', 3'-diphosphate and 3', 4'-diphosphate). Both compounds lack the methoxy group at the 4' position of the B-ring. Kevin's lab has prepared the ZSB-Target-36 (2',3'-diphosphate-4'-hydrogen) CA-1 analog. The compound (19.2 mg) was shipped to Klaus on 9/3/02. The MTT values for ZSB-Target-36 were >44.8 and 0.4 μ M at 1 hour and 5 days, respectively. The 3', 4'-diphosphate (4' H; ZSB-Target-37) is currently undergoing deprotection in Dr. Kane's lab. Bob stated that ZSB-Target-37 (15-20 mg) will be shipped to Klaus the week of 9/16/02.
- Bob Kane's group has resynthesized the 2' fluoro; 3' phosphate; 4' methoxy CA1 analog (ZSB-Target-41). The compound was shipped to Klaus for MTT and blood flow shutdown analysis the week of 9/3/02. The MTT values for ZSB-Target-41 were 8 and 0.015 μ M at 1 hour and 5 days, respectively.